Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial
Summary
CONCLUSIONS MRLN sparing radiotherapy maintained uncompromised efficacy and better long term swallowing function by reducing radiation damage to pharyngeal contractors, supporting its use as a standard of care for non-metastatic nasopharyngeal carcinoma. TRIAL REGISTRATION ClinicalTrials.gov NCT03346109.
Content
# Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial
*Published: 2026 Mar 31*
## CONCLUSIONS
MRLN sparing radiotherapy maintained uncompromised efficacy and
better long term swallowing function by reducing radiation damage to pharyngeal
contractors, supporting its use as a standard of care for non-metastatic
nasopharyngeal carcinoma.
## TRIAL REGISTRATION
ClinicalTrials.gov NCT03346109.
DOI: 10.1136/bmj-2025-086050